Phase II trial of Nexavar in combo with chemotherapy shows free survival benefits in breast cancer patients
Friday, July 24, 2009 10:00 IST Berlin
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc announced that their first cooperative group-sponsored randomized phase-II trial in advanced metastatic breast cancer met its primary endpoint of progression-free survival.